All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The Texas Heart Institute Center for Cardiovascular Care has divulged piperazine-based integrin αLβ2 (LFA-1) and/or integrin α4β1 (ITGA4; VLA-4) agonists reported to be useful for the treatment of diabetes, infertility, pulmonary hypertension, renal failure, myocardial infarction, spinal cord injury, pulmonary fibrosis and Parkinson's diseases.
